TheraRadar

Norgine

Pre-Approval PRO BETA
30
Total Trials
9
Phase 3
5
Phase 2
1
Recruiting
225
Score

Pipeline by Phase

Phase 3
9
Phase 2
5
Phase 1
15

Therapeutic Focus

Colorectal Cancer Fecal Incontinence Colorectal Carcinoma Colon Cleansing Colon Cancer

Clinical Trials (30)

NCT07218523 Phase 3 RECRUITING

A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy

Started: 12/29/2025

NCT01710982 Phase 3 COMPLETED

Study to Evaluate the Safety of Post-Operative TZP-101 (IV Ulimorelin) After Partial Bowel Resection

Started: 2/1/2012

NCT02273167 Phase 3 COMPLETED

Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.

Started: 10/1/2014

NCT02254486 Phase 3 COMPLETED

Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults

Started: 9/1/2014

NCT02273141 Phase 3 COMPLETED

Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults.

Started: 11/1/2014

NCT01493089 Phase 3 COMPLETED

Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease

Started: 4/1/2011

NCT01251822 Phase 3 COMPLETED

Comparator Study of PEG 3350 Versus Prucalopride in Females With Chronic Constipation

Started: 11/1/2010

NCT00796354 Phase 3 COMPLETED

Constipation Associated With Irritable Bowel Syndrome (IBS-C)

Started: 11/1/2008

NCT00794482 Phase 3 COMPLETED

Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.

Started: 3/1/2008

NCT00794716 Phase 2 COMPLETED

PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)

Started: 6/1/2008

NCT01656720 Phase 2 COMPLETED

A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period

Started: 2/1/2012

NCT01714466 Phase 2 COMPLETED

Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy

Started: 10/1/2012

NCT01251237 Phase 2 COMPLETED

Study to Assess the Tolerability, Safety and Efficacy of an Adapted Gut Cleansing Solution in Routine Colon Cleansing Prior to Colonoscopies

Started: 3/1/2010

NCT00915057 Phase 2 COMPLETED

Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972.

Started: 3/1/2009

NCT03437265 Phase 1 COMPLETED

A Pharmacokinetic Study of PLENVU® in Healthy Subjects

Started: 9/3/2020

NCT01164332 Phase 1 COMPLETED

Sensitivity of Alternative NRL972 Detection Methods in Healthy Subjects

Started: 7/1/2010

NCT01834742 Phase 1 COMPLETED

Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects

Started: 4/1/2011

NCT01715272 Phase 1 COMPLETED

A Clinical Investigation to Demonstrate the Performance of a New Enema (TF037) in Distal Bowel Cleansing Compared With Fleet Enema

Started: 10/1/2012

NCT01175941 Phase 1 COMPLETED

Effect of 7 Days of Dosing With a 10 mg Rectal Suppository of NRL001in Patients With Faecal Incontinence

Started: 8/1/2010

NCT01710995 Phase 1 COMPLETED

A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions

Started: 10/1/2010

NCT01405599 Phase 1 COMPLETED

Evaluation of the Pharmacokinetics of Ulimorelin in Subjects With Hepatic Impairment and Healthy Subjects

Started: 6/1/2011

NCT01405612 Phase 1 COMPLETED

Study to Examine the Effect of Ulimorelin on the Pharmacokinetics of Midazolam in Healthy Volunteers

Started: 6/1/2011

NCT01668199 Phase 1 COMPLETED

A Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery and Pharmacokinetics of 14C TZP-101

Started: 2/1/2012

NCT01099670 Phase 1 COMPLETED

Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of 7.5, 10, 12.5 or 15 mg NRL001 in a 2 g Suppository for 14 Days

Started: 3/1/2010

NCT01099683 Phase 1 COMPLETED

Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of a Single Rectal Application of 10 mg NRL001 in Elderly Subjects

Started: 4/1/2010

NCT00896597 Phase 1 COMPLETED

Reproducibility of Child-Turcotte-Pugh (CTP) Rating and NRL972 Pharmacokinetics in Patients With Cirrhosis

Started: 4/1/2009

NCT00850590 Phase 1 COMPLETED

Study of Escalating Doses of NRL001 Given in Slow-release Rectal Suppositories of Different Weights

Started: 2/1/2009

NCT00857467 Phase 1 COMPLETED

Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001.

Started: 2/1/2009

NCT00868985 Phase 1 COMPLETED

Effects of Oral PEG 3350 on Electrolyte Balance

Started: 1/1/2008

NCT01689792 Phase 4 COMPLETED

A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)

Started: 11/1/2011

Drug Candidates

PLENVU® Sodium picosulfate TZP-101 NRL972 PLENVU powder for oral solution NER1006, 2-Day Split-Dosing NER1006,1-Day Morning Split-Dosing MOVIPREP, 2-Day Split-Dosing NER1006 Trisulfate solution
Activity Status: Active
Last Trial Started: 12/29/2025
Last Trial Ended: 10/5/2020
Trials (12 months): 1
Completed Trials: 29
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.